Kevin Lundquist serves as Abzena’s CFO and oversees Abzena’s global finance and fiscal health of the business.
Kevin has primary responsibility for planning, implementing, managing, and running of all the finance activities at Abzena. Kevin manages our capital investments, investor relations and partnership compliance with Welsh, Carson, Anderson, and Stowe (WCAS).
With 25+ years of experience in the financial industry across healthcare and technology sectors, Kevin has held various positions of increasing seniority including a leadership role at Genentech/Roche where he was the Senior Director of Finance, Global Drug Substance Manufacturing Operations. Prior to joining Abzena, he was the Vice President of Finance at Revance Therapeutics.
Kevin has his B.S. in Accounting and Finance from the University of Utah, USA and his master’s degree in Business Administration (MBA) from Utah State University.